Landscape Capital Management L.L.C. Purchases 12,395 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Landscape Capital Management L.L.C. boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 312.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,358 shares of the medical equipment provider's stock after purchasing an additional 12,395 shares during the period. Landscape Capital Management L.L.C.'s holdings in Lantheus were worth $1,463,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus in the 3rd quarter valued at about $25,000. Kestra Investment Management LLC bought a new stake in shares of Lantheus during the 4th quarter worth about $27,000. Summit Securities Group LLC bought a new stake in Lantheus in the 4th quarter valued at $37,000. UMB Bank n.a. boosted its position in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after acquiring an additional 134 shares during the period. Finally, World Investment Advisors LLC acquired a new position in shares of Lantheus in the third quarter valued at about $60,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on LNTH shares. B. Riley decreased their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. The Goldman Sachs Group began coverage on Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective for the company. JMP Securities reissued a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial upped their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $129.43.

Lantheus Stock Performance

Shares of Lantheus stock traded down $4.36 on Thursday, hitting $95.80. The company had a trading volume of 234,931 shares, compared to its average volume of 890,118. The stock has a market capitalization of $6.56 billion, a price-to-earnings ratio of 15.97 and a beta of 0.20. Lantheus Holdings, Inc. has a 1 year low of $59.56 and a 1 year high of $126.89. The stock has a 50 day moving average of $93.62 and a 200-day moving average of $95.76.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Buying and Selling at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock valued at $6,110,806 in the last 90 days. 1.50% of the stock is currently owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.